Home » Stocks » Insmed

Insmed, Inc. (INSM)

Stock Price: $36.89 USD -0.10 (-0.27%)
Updated Oct 26, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 3.74B
Revenue (ttm) 163.95M
Net Income (ttm) -241.89M
Shares Out 101.48M
EPS (ttm) -2.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 26, 2020
Last Price $36.89
Previous Close $36.99
Change ($) -0.10
Change (%) -0.27%
Day's Open 36.29
Day's Range 35.88 - 37.20
Day's Volume 618,729
52-Week Range 12.09 - 39.39

More Stats

Market Cap 3.74B
Enterprise Value 3.50B
Earnings Date (est) Oct 29, 2020
Ex-Dividend Date n/a
Shares Outstanding 101.48M
Float 98.52M
EPS (basic) -2.64
EPS (diluted) -2.65
FCF / Share -2.31
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 11.28M
Short Ratio 11.62
Short % of Float 11.45%
Beta 2.49
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 22.83
PB Ratio 9.36
Revenue 163.95M
Operating Income -218.04M
Net Income -241.89M
Free Cash Flow -222.85M
Net Cash 243.15M
Net Cash / Share 2.40
Gross Margin 68.47%
Operating Margin -132.99%
Profit Margin -147.50%
FCF Margin -135.93%
ROA -16.15%
ROE -63.50%
ROIC -42.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 8
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$45.50*
(23.34% upside)
Low
35.0
Current: $36.89
High
56.0
Target: 45.50
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue1369.84----11.50-4.426.92
Revenue Growth1287.56%--------36.18%-
Gross Profit1127.41----11.50-4.426.92
Operating Income-235-307-189-173-117-87.37-55.02-42.44-61.72-8.09
Net Income-254-324-193-176-118-79.16-56.07-41.37-59.66-6.43
Shares Outstanding84.5676.8966.5861.8958.6343.1034.9826.5523.3513.25
Earnings Per Share-3.01-4.22-2.89-2.85-2.02-1.84-1.60-1.56-2.95-0.49
Operating Cash Flow-251-258-160-147-101-64.42-46.66-31.01-30.21-7.72
Capital Expenditures-42.27-13.09-3.00-4.20-3.45-5.34-0.82-0.29-0.98-
Free Cash Flow-293-271-163-151-104-69.76-47.49-31.30-31.18-7.72
Cash & Equivalents48749538116328315911492.9476.27108
Total Debt39731755.5754.7925.1424.8619.6919.390.280.16
Net Cash / Debt90.3917932610825813494.2173.5575.99108
Assets742605462238357231176154140196
Liabilities48139610183.4744.8644.6333.1732.685.573.42
Book Value262208361154312186143121134193
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Insmed, Inc.
Country United States
Employees 435
CEO William H. Lewis

Stock Information

Ticker Symbol INSM
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: INSM
IPO Date June 1, 2000

Description

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients in the United States. It also develops INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug for the treatment of rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.